



Companion Diagnostics: From Biomarker Identification to Market Entry

APR
28-29
2014

www.nyas.org/CDx2014

The recent growth in complex biological data has enabled a major paradigm shift in healthcare away from “one-size-fits-all” approaches towards customized, patient-tailored therapies. Biomarker-based companion diagnostics (CDx) lie at the heart of this personalized, precision medicine movement. This 2-day conference will provide a neutral forum to discuss research, financial, and regulatory strategies that will facilitate CDx development and integration into clinical care. Presentations will illustrate successes and failures based on case studies; evaluate emerging applications of technologies such as epigenetics, bioinformatics, and nanotechnology; analyze diverse therapeutic target areas beyond cancer including inflammatory, infectious, cardiovascular, metabolic, and neurodegenerative diseases; recognize regulatory hurdles; and formulate solutions to better improve public health with CDx and personalized medicine.

Call for Abstracts and Travel Fellowship Applications

Deadline: **March 14, 2014.**

Select abstracts will be chosen for oral presentation.

Silver Sponsor: 

Chair, Organizing Committee

Claudio Carini, MD, PhD, Pfizer Inc

Organizers

Melanie Brickman Stynes, PhD, MSc, The New York Academy of Sciences

David A. Fryburg, MD, Selventa

Brooke Grindlinger, PhD, The New York Academy of Sciences

Kerstin Hofmeyer, PhD, The New York Academy of Sciences

Raju Kucherlapati, PhD, Harvard Medical School

Iain McInnes, FRCP, PhD, FRSE, University of Glasgow

Michael A. Pacanowski, PharmD, MPH, U.S. Food and Drug Administration

Peter Parker, MD, King's College London

Andras Perl, MD, PhD, SUNY Upstate Medical University

Tariq Sethi, BSc, MA, PhD, FRCP, King's College School of Medicine

Keynote Panelists

Christopher P. Austin, MD, National Center for Advancing Translational Sciences / NIH

Mikael Dolsten, MD, PhD, Pfizer Inc

Michael Kolodziej, MD, FACP, Aetna

Charles L. Sawyers, MD, Memorial Sloan-Kettering Cancer Center

Speakers

Aram Adourian, PhD, BG Medicine, Inc

Naomi Aronson, PhD, Blue Cross and Blue Shield Association

Erwin P. Böttinger, MD, Icahn School of Medicine at Mount Sinai

Angela Brand, MD, PhD, MPH, Maastricht University, Institute for Public Health Genomics

Mark J. Caulfield, MD, Barts and The London School of Medicine and Dentistry

Michael Corbo, PhD, Pfizer Inc

Philip Lawrence De Jager, MD, PhD, Harvard Medical School

Dusko Ehrlich, PhD, Institut National de la Recherche Agronomique (INRA)

Federico Goodsaid, PhD, Vertex Pharmaceuticals

Julie A. Johnson, PharmD, FCCP, BCPS, University of Florida

Bruce W. M. Jordan, PhD, Roche Diagnostics

Charles Knirsch, MD, MPH, Pfizer Inc

Massimo Loda, MD, Dana-Farber Cancer Institute

Tom Lowery, PhD, T2 Biosystems

Eugene O. Major, PhD, National Institute of Neurological Disorders and Stroke / NIH

Kenneth Marek, MD, Institute for Neurodegenerative Disorders

Jane Mellor, PhD, University of Oxford

Michelle M. Milke, PhD, Mayo Clinic

Robert M. Plenge, MD, PhD, Merck Research Laboratories

Dan Roden, MD, Vanderbilt University School of Medicine

Hakan Sakul, PhD, Pfizer Inc

Daniela Starcevic, PhD, Icahn School of Medicine at Mount Sinai

Location

The New York Academy of Sciences
7 World Trade Center
250 Greenwich St., 40th Floor
New York, NY 10007-2157

Sponsorship Opportunities

contact: **Kerstin Hofmeyer**, PhD
at khofmeyer@nyas.org
or 212.298.8610